Novartis Battles Image Problem In Japan As Data Manipulation Questions Remain
This article was originally published in PharmAsia News
Executive Summary
Novartis Pharmaceuticals Head David Epstein visited Tokyo to announce salary cuts to the company’s top Japan staff and to introduce a new Japan chairman after acknowledging undisclosed conflict of interest in recalled Diovan studies. But the company is still dogged by its involvement in data manipulation and improper advertising after interim results from a MHLW investigation.